Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Fendler WP, et al. Among authors: gartmann j. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. JAMA Oncol. 2019. PMID: 30920593 Free PMC article. Clinical Trial.
Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.
Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Calais J, et al. Among authors: gartmann j. J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14. J Nucl Med. 2018. PMID: 29242398 Free PMC article.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Calais J, et al. Among authors: gartmann j. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Lancet Oncol. 2019. PMID: 31375469 Free PMC article. Clinical Trial.
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. Fendler WP, et al. Among authors: gartmann j. J Nucl Med. 2020 Dec;61(12):1793-1799. doi: 10.2967/jnumed.120.242180. Epub 2020 May 1. J Nucl Med. 2020. PMID: 32358094 Free PMC article. Clinical Trial.
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. Calais J, et al. Among authors: gartmann j. J Nucl Med. 2021 Oct;62(10):1440-1446. doi: 10.2967/jnumed.121.261982. Epub 2021 May 20. J Nucl Med. 2021. PMID: 34016732 Free PMC article.
Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.
Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. Calais J, et al. Among authors: gartmann j. J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4. J Nucl Med. 2017. PMID: 28473600 Free PMC article.
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. Calais J, et al. Among authors: gartmann j. J Nucl Med. 2021 Oct;62(10):1447-1456. doi: 10.2967/jnumed.121.262543. Epub 2021 Jul 16. J Nucl Med. 2021. PMID: 34272322 Free PMC article.
[Antitubercular agents].
Gartmann J. Gartmann J. Ther Umsch. 1999 Dec;56(12):687-90. doi: 10.1024/0040-5930.56.12.687. Ther Umsch. 1999. PMID: 10638274 Review. German.
74 results